Preparation method of deuterated drug impurity O-desmethylvenlafaxin-d10

By using venlafaxine in drug research and development, combined with palladium-carbon catalysis and demethylation of lithium aluminum hydride, column chromatography and thin layer chromatography separation, nuclear magnetic resonance spectroscopy confirmed the deuterated condition, and O- The lack of selectivity and yield in the preparation method of demethylvenlafaxine-d10 has achieved high-purity preparation of deuterated drug impurities and enhanced the application value of drug research and development.

CN118930441AInactive Publication Date: 2024-11-12JIANGYIN BUILDING BLOCKS NEW MATERIAL TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410857464.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-28
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The preparation method of O-demethylvenlafaxine-d10 has problems of selectivity and insufficient yield, which limits its application in drug development.

Method used

Venlafaxine and deuterated reagent are used to react in the presence of a catalyst. After demethylation, purification, deuterated confirmation, crystallization and drying, palladium carbon is used as the catalyst and lithium aluminum hydride is used as the demethylation reagent. Anhydrous ether or anhydrous ethanol is used as an inert solvent and is separated by column chromatography and thin layer chromatography. Nuclear magnetic resonance spectroscopy confirms the deuterated condition to ensure the high purity and quality of the product.

Benefits of technology

It significantly improves the selectivity and yield of O-demethylvenlafaxine-d10, provides high-purity deuterated drug impurities, and enhances the application value in drug research and development.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a preparation method of a deuterated drug impurity O-desmethylvenlafaxin-d10, and belongs to the technical field of medicines. The preparation method of the deuterated drug impurity O-demethylvenlafaxin-d10 comprises the following steps: S1, raw material preparation: obtaining a deuterated substance of venlafaxine as a starting material, and reacting venlafaxine with a deuterated reagent in the presence of a catalyst to obtain deuterated venlafaxine; s2, demethylation reaction: carrying out reaction on the deuterated venlafaxine and a demethylation reagent in an inert solvent to remove methyl; s3, purification: purifying the demethylated product; s4, confirming deuteration; s5, crystallizing and drying; s6, quality control; the inert atmosphere is adopted as a reaction environment to ensure that the catalyst does not react with reactants, so that the selectivity and efficiency of the reaction are maintained, the purity and yield of the product can be remarkably improved, and a more reliable and efficient tool compound is provided for drug research and development.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of medicine, and in particular to a method for preparing a deuterated drug impurity O-desmethylvenlafaxine-d10. Background Art

[0002] At present, venlafaxine is a phenylethylamine derivative and a bicyclic atypical antidepressant. This product and its active metabolite O-desmethylvenlafaxine (ODV) can effectively antagonize the reuptake of 5-HT and NA, and also have a certain effect on the reuptake of DA, and have an antidepressant effect. The sedative effect is weak. It is well absorbed orally, and eating does not affect the absorption of the drug;

[0003] Deuterated drugs are important tool compounds in drug development and are used in pharmacokinetic studies, radiolabeling, and pharmacodynamic studies. O-desmethylvenlafaxine-d10, as a specific deuterated drug impurity, plays an important role in drug metabolism and pharmacodynamic mechanism studies;

[0004] The above-mentioned prior art solutions have the following defects: the preparation method of O-desmethylvenlafaxine-d10 has the problems of insufficient selectivity and yield, which limits its application in drug research and development. Summary of the invention

[0005] In order to make up for the above shortcomings, the present application provides a method for preparing a deuterated drug impurity O-desmethylvenlafaxine-d10, aiming to improve the problems of insufficient selectivity and yield in the preparation method of O-desmethylvenlafaxine-d10.

[0006] The present invention provides a method for preparing a deuterated drug impurity O-desmethylvenlafaxine-d10, comprising the following steps:

[0007] S1. Raw material preparation: obtaining a deuterated product of venlafaxine as a starting material, and reacting venlafaxine with a deuterated reagent in the presence of a catalyst to obtain deuterated venlafaxine;

[0008] S2, demethylation reaction: reacting deuterated venlafaxine with a demethylation agent in an inert solvent to remove the methyl group;

[0009] S3, purification: purifying the demethylated product to separate the target compound O-desmethylvenlafaxine;

[0010] S4. Deuterium confirmation: Use nuclear magnetic resonance (NMR) spectroscopy to confirm the deuterium status of the target compound, so as to facilitate the observation of the NMR signal of deuterium in the target compound;

[0011] S5, crystallization and drying: crystallizing the confirmed O-desmethylvenlafaxine-d10 to obtain a high-purity product, and then drying it to obtain a final product;

[0012] S6. Quality control: Conduct quality analysis on the final product, including quantitative analysis, melting point determination, spectral analysis, etc., to ensure that the product meets the specified quality standards.

[0013] In a preferred embodiment of the present invention, the deuterated reagent is deuterated methane or deuterium gas (D2gas), and the catalyst is an inert atmosphere.

[0014] Deuterated reagents include deuterated methane or deuterium gas (D2 gas). Due to their deuterated characteristics, these two reagents can effectively simulate the isotope effect under real reaction conditions and provide accurate data for research. In terms of catalysts, an inert atmosphere is used as the reaction environment to ensure that the catalyst does not react with the reactants, thereby maintaining the selectivity and efficiency of the reaction.

[0015] In a preferred embodiment of the present invention, the catalyst is palladium carbon, the demethylation agent is lithium aluminum hydride LiAl H4, and the inert solvent is anhydrous ether, anhydrous ethanol or N,N-dimethylformamide.

[0016] Palladium carbon was used as a catalyst, lithium aluminum hydride LiAl H4 was used as a demethylation agent, and anhydrous ether, anhydrous ethanol or N,N-dimethylformamide was used as an inert solvent. The system showed excellent activity and selectivity in the demethylation reaction, and could efficiently convert methyl-containing compounds into corresponding demethylation products. The addition of palladium carbon not only increased the reaction rate, but also enhanced the reusability of the catalyst. Lithium aluminum hydride LiAl H4, as a strong reducing agent, can effectively remove methyl groups from the compound. Anhydrous ether, anhydrous ethanol or N,N-dimethylformamide was used as an inert solvent to stabilize the reaction system and reduce the occurrence of side reactions. It is suitable for the demethylation of a variety of organic compounds and provides a new and efficient tool for the field of organic synthesis.

[0017] In a preferred embodiment of the present invention, the purification of the demethylated product comprises separation by column chromatography or thin layer chromatography.

[0018] The demethylated product is purified by column chromatography and thin layer chromatography, which are two commonly used separation techniques that can effectively separate the target compound from a complex mixture. Column chromatography uses the differences in properties such as polarity, size, and distribution coefficient of different compounds to separate the compounds into different components through the interaction between the stationary phase and the mobile phase. Thin layer chromatography uses the stationary phase on the adsorbent to separate the compounds in the sample through the movement of the solvent. Both methods require precise operating conditions and appropriate solvent systems to ensure the separation effect. The purified product can be used for subsequent analysis, characterization, or further synthesis.

[0019] In a preferred embodiment of the present invention, the product is separated and purified by column chromatography to obtain O-desmethylvenlafaxine-d1 with a purity of ≥95%.

[0020] Column chromatography is a commonly used method for separating and purifying compounds by utilizing the different affinities of different compounds between the stationary phase and the mobile phase. A method for separating and purifying O-desmethylvenlafaxine-d1 by column chromatography, which can ensure the purity of the product ≥95%. First, we selected a specific adsorbent as the stationary phase, which has high selectivity and good separation effect. Then, by optimizing the loading concentration, flow rate and elution conditions, the target compound O-desmethylvenlafaxine-d1 can be effectively separated from other impurities. Finally, by collecting the elution peak and properly treating it, O-desmethylvenlafaxine-d1 with a purity of ≥95% can be obtained. This method has the advantages of simple operation, low cost, good reproducibility, etc., and is suitable for large-scale production.

[0021] In a preferred embodiment of the present invention, in S4, nuclear magnetic resonance (NMR) spectroscopy is used to confirm the deuteration status of the target compound, and a deuterated solvent is used to perform the NMR test.

[0022] Confirming the deuteration status of a target compound usually involves the use of nuclear magnetic resonance (NMR) spectroscopy. In NMR spectroscopy, deuterium (D), as a stable isotope, has nuclei with the same number of protons but different numbers of neutrons, and therefore has different magnetic properties. When the target compound reacts with a deuterated solvent (i.e., a solvent containing deuterium, such as deuterated water D2O or deuterated methanol CD3OD), the deuterium atoms in the deuterated solvent replace the hydrogen atoms in the compound. Subsequently, through NMR testing, signals of the deuterated compound in specific chemical shift regions can be observed, which are different from the hydrogen atom signals in the original compound. This difference provides direct evidence that the hydrogen atoms in the compound are replaced by deuterium atoms, thereby accurately determining the deuteration status of the hydrogen atoms in the target compound.

[0023] In a preferred embodiment of the present invention, the reaction conditions included in S1 and S2 are: temperature 20-30° C., pressure 1-3 atm, and reaction time 4-6 hours.

[0024] The temperature range is set to 20-30°C, the pressure is 1-3atm, and the reaction time is 4-6 hours. These conditions ensure the efficient conduct of the reaction, while reducing the formation of by-products and improving the purity and yield of the target product. By precisely controlling these parameters, the reaction process can be optimized to achieve higher chemical conversion rates and better product quality. The method is easy to operate, cost-effective and environmentally friendly.

[0025] In a preferred embodiment of the present invention, the preparation of venlafaxine comprises

[0026] a. Add 300 mL of solvent, 20 g of NaOH, and 12.5-30 g of catalyst to a reaction vessel, stir for 15-30 min, cool to 10-20 ° C, add 150 g of 2-(4-methoxyphenyl)ethylamine and 100-200 g of cyclohexanone, stir for 3-4 h at 10-20 ° C, add 900-1000 mL of deionized water, stir for 30-40 min, filter, and dry at 55 ° C to obtain an intermediate;

[0027] b. Add 160-250 g of the intermediate, 1000 mL of deionized water, 200-300 mL of formic acid, and 150-200 mL of methanol to a reaction vessel, heat to reflux, stir for 20-30 h, recover the solvent under reduced pressure until dry, add 400-600 mL of deionized water and 400-600 mL of ethyl acetate, adjust the pH to 10 with a 10% NaOH aqueous solution, allow to stand for stratification, collect the upper organic phase, dry over anhydrous sodium sulfate, filter, add 120-180 mL of salt solution to the filtrate at 5-15 ° C, stir and crystallize for 2-3.5 h, filter, and wash the filter cake with ethyl acetate to obtain venlafaxine.

[0028] In a preferred embodiment of the present invention, the solvent in step a is prepared by mixing deionized water and methanol in a volume ratio of 1:1; the catalyst is any one of PEG, cyclodextrin, benzyltriethylammonium chloride, tetrabutylammonium bromide, and tetrabutylammonium chloride.

[0029] In a preferred embodiment of the present invention, the mass ratio of the upper organic phase to anhydrous sodium sulfate is 100:1-2; the salt-forming solution in step b is 30% by mass of isopropyl hydrochloride.

[0030] Beneficial effects: The present application provides a method for preparing a deuterated drug impurity O-desmethylvenlafaxine-d10, comprising reacting a venlafaxine precursor compound with a deuterated reagent in the presence of a catalyst to improve the selectivity and yield of the reaction; obtaining the target deuterated impurity O-desmethylvenlafaxine-d10 by separating and purifying the reaction product; a highly selective method for preparing the deuterated drug impurity O-desmethylvenlafaxine-d10; using an inert atmosphere as a reaction environment to ensure that the catalyst does not react with the reactants, thereby maintaining the selectivity and efficiency of the reaction, being able to significantly improve the purity and yield of the product, and providing a more reliable and efficient tool compound for drug research and development. DETAILED DESCRIPTION

[0031] The technical solutions in the embodiments of the present application are described below.

[0032] The present invention provides a method for preparing a deuterated drug impurity O-desmethylvenlafaxine-d10, comprising the following steps:

[0033] S1. Raw material preparation: obtaining a deuterated product of venlafaxine as a starting material, and reacting venlafaxine with a deuterated reagent in the presence of a catalyst to obtain deuterated venlafaxine;

[0034] S2, demethylation reaction: reacting deuterated venlafaxine with a demethylation agent in an inert solvent to remove the methyl group;

[0035] S3, purification: purifying the demethylated product to separate the target compound O-desmethylvenlafaxine;

[0036] S4. Deuterium confirmation: Use nuclear magnetic resonance (NMR) spectroscopy to confirm the deuterium status of the target compound, so as to facilitate the observation of the NMR signal of deuterium in the target compound;

[0037] S5, crystallization and drying: crystallizing the confirmed O-desmethylvenlafaxine-d10 to obtain a high-purity product, and then drying it to obtain a final product;

[0038] S6. Quality control: Conduct quality analysis on the final product, including quantitative analysis, melting point determination, spectral analysis, etc., to ensure that the product meets the specified quality standards.

[0039] In a preferred embodiment of the present invention, the deuterated reagent is deuterated methane or deuterium gas (D2gas), and the catalyst is an inert atmosphere.

[0040] Deuterated reagents include deuterated methane or deuterium gas (D2 gas). Due to their deuterated characteristics, these two reagents can effectively simulate the isotope effect under real reaction conditions and provide accurate data for research. In terms of catalysts, an inert atmosphere is used as the reaction environment to ensure that the catalyst does not react with the reactants, thereby maintaining the selectivity and efficiency of the reaction.

[0041] In a preferred embodiment of the present invention, the catalyst is palladium carbon, the demethylation agent is lithium aluminum hydride LiAl H4, and the inert solvent is anhydrous ether, anhydrous ethanol or N,N-dimethylformamide.

[0042] Palladium carbon was used as a catalyst, lithium aluminum hydride LiAl H4 was used as a demethylation agent, and anhydrous ether, anhydrous ethanol or N,N-dimethylformamide was used as an inert solvent. The system showed excellent activity and selectivity in the demethylation reaction, and could efficiently convert methyl-containing compounds into corresponding demethylation products. The addition of palladium carbon not only increased the reaction rate, but also enhanced the reusability of the catalyst. Lithium aluminum hydride LiAl H4, as a strong reducing agent, can effectively remove methyl groups from the compound. Anhydrous ether, anhydrous ethanol or N,N-dimethylformamide was used as an inert solvent to stabilize the reaction system and reduce the occurrence of side reactions. It is suitable for the demethylation of a variety of organic compounds and provides a new and efficient tool for the field of organic synthesis.

[0043] In a preferred embodiment of the present invention, the purification of the demethylated product comprises separation by column chromatography or thin layer chromatography.

[0044] The demethylated product is purified by column chromatography and thin layer chromatography, which are two commonly used separation techniques that can effectively separate the target compound from a complex mixture. Column chromatography uses the differences in properties such as polarity, size, and distribution coefficient of different compounds to separate the compounds into different components through the interaction between the stationary phase and the mobile phase. Thin layer chromatography uses the stationary phase on the adsorbent to separate the compounds in the sample through the movement of the solvent. Both methods require precise operating conditions and appropriate solvent systems to ensure the separation effect. The purified product can be used for subsequent analysis, characterization, or further synthesis.

[0045] In a preferred embodiment of the present invention, the product is separated and purified by column chromatography to obtain O-desmethylvenlafaxine-d1 with a purity of ≥95%.

[0046] Column chromatography is a commonly used method for separating and purifying compounds by utilizing the different affinities of different compounds between the stationary phase and the mobile phase. A method for separating and purifying O-desmethylvenlafaxine-d1 by column chromatography, which can ensure the purity of the product ≥95%. First, we selected a specific adsorbent as the stationary phase, which has high selectivity and good separation effect. Then, by optimizing the loading concentration, flow rate and elution conditions, the target compound O-desmethylvenlafaxine-d1 can be effectively separated from other impurities. Finally, by collecting the elution peak and properly treating it, O-desmethylvenlafaxine-d1 with a purity of ≥95% can be obtained. This method has the advantages of simple operation, low cost, good reproducibility, etc., and is suitable for large-scale production.

[0047] In a preferred embodiment of the present invention, in S4, nuclear magnetic resonance (NMR) spectroscopy is used to confirm the deuteration status of the target compound, and a deuterated solvent is used to perform the NMR test.

[0048] Confirming the deuteration status of a target compound usually involves the use of nuclear magnetic resonance (NMR) spectroscopy. In NMR spectroscopy, deuterium (D), as a stable isotope, has nuclei with the same number of protons but different numbers of neutrons, and therefore has different magnetic properties. When the target compound reacts with a deuterated solvent (i.e., a solvent containing deuterium, such as deuterated water D2O or deuterated methanol CD3OD), the deuterium atoms in the deuterated solvent replace the hydrogen atoms in the compound. Subsequently, through NMR testing, signals of the deuterated compound in specific chemical shift regions can be observed, which are different from the hydrogen atom signals in the original compound. This difference provides direct evidence that the hydrogen atoms in the compound are replaced by deuterium atoms, thereby accurately determining the deuteration status of the hydrogen atoms in the target compound.

[0049] In a preferred embodiment of the present invention, the reaction conditions included in S1 and S2 are: temperature 20-30° C., pressure 1-3 atm, and reaction time 4-6 hours.

[0050] The temperature range is set to 20-30°C, the pressure is 1-3atm, and the reaction time is 4-6 hours. These conditions ensure the efficient conduct of the reaction, while reducing the formation of by-products and improving the purity and yield of the target product. By precisely controlling these parameters, the reaction process can be optimized to achieve higher chemical conversion rates and better product quality. The method is easy to operate, cost-effective and environmentally friendly.

[0051] In a preferred embodiment of the present invention, the preparation of venlafaxine comprises

[0052] a. Add 300 mL of solvent, 20 g of NaOH, and 12.5-30 g of catalyst to a reaction vessel, stir for 15-30 min, cool to 10-20 ° C, add 150 g of 2-(4-methoxyphenyl)ethylamine and 100-200 g of cyclohexanone, stir for 3-4 h at 10-20 ° C, add 900-1000 mL of deionized water, stir for 30-40 min, filter, and dry at 55 ° C to obtain an intermediate;

[0053] b. Add 160-250 g of the intermediate, 1000 mL of deionized water, 200-300 mL of formic acid, and 150-200 mL of methanol to a reaction vessel, heat to reflux, stir for 20-30 h, recover the solvent under reduced pressure until dry, add 400-600 mL of deionized water and 400-600 mL of ethyl acetate, adjust the pH to 10 with a 10% NaOH aqueous solution, allow to stand for stratification, collect the upper organic phase, dry over anhydrous sodium sulfate, filter, add 120-180 mL of salt solution to the filtrate at 5-15 ° C, stir and crystallize for 2-3.5 h, filter, and wash the filter cake with ethyl acetate to obtain venlafaxine.

[0054] In a preferred embodiment of the present invention, the solvent in step a is prepared by mixing deionized water and methanol in a volume ratio of 1:1; the catalyst is any one of PEG, cyclodextrin, benzyltriethylammonium chloride, tetrabutylammonium bromide, and tetrabutylammonium chloride.

[0055] In a preferred embodiment of the present invention, the mass ratio of the upper organic phase to anhydrous sodium sulfate is 100:1-2; the salt-forming solution in step b is 30% by mass of isopropyl hydrochloride.

[0056] Specifically, venlafaxine precursor compound and deuterated reagent are used as raw materials, and the reaction is carried out in the presence of palladium carbon catalyst in N,N-dimethylformamide solvent, and the reaction conditions are: temperature 25°C, pressure 1atm, and reaction time 4 hours. By optimizing the reaction conditions and catalyst, the purity and yield of the product can be significantly improved.

[0057] The above description is only an embodiment of the present application and is not intended to limit the protection scope of the present application. For those skilled in the art, the present application may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application shall be included in the protection scope of the present application.

Claims

1. A method for preparing a deuterated drug impurity O-desmethylvenlafaxine-d10, characterized in that: The following steps are included S1. Raw material preparation: obtaining a deuterated product of venlafaxine as a starting material, and reacting venlafaxine with a deuterated reagent in the presence of a catalyst to obtain deuterated venlafaxine; S2, demethylation reaction: reacting deuterated venlafaxine with a demethylation agent in an inert solvent to remove the methyl group; S3, purification: purifying the demethylated product to separate the target compound O-desmethylvenlafaxine; S4. Deuterium confirmation: Use nuclear magnetic resonance (NMR) spectroscopy to confirm the deuterium status of the target compound, so as to facilitate the observation of the NMR signal of deuterium in the target compound; S5, crystallization and drying: crystallizing the confirmed O-desmethylvenlafaxine-d10 to obtain a high-purity product, and then drying it to obtain a final product; S6. Quality control: Conduct quality analysis on the final product, including quantitative analysis, melting point determination, spectral analysis, etc., to ensure that the product meets the specified quality standards.

2. The method for preparing a deuterated drug impurity O-desmethylvenlafaxine-d10 according to claim 1, characterized in that: The deuterated reagent is deuterated methane or deuterium gas (D2 gas), and the catalyst is an inert atmosphere.

3. A method for preparing a deuterated drug impurity O-desmethylvenlafaxine-d10 according to claim 1 or 2, characterized in that: The catalyst is palladium carbon, the demethylation agent is lithium aluminum hydride LiAlH4, and the inert solvent is anhydrous ether, anhydrous ethanol or N,N-dimethylformamide.

4. The method for preparing a deuterated drug impurity O-desmethylvenlafaxine-d10 according to claim 1, characterized in that: The demethylated product is purified by column chromatography and thin layer chromatography.

5. The method for preparing a deuterated drug impurity O-desmethylvenlafaxine-d10 according to claim 1, characterized in that: The product was separated and purified by column chromatography to obtain O-desmethylvenlafaxine-d1 with a purity of ≥95%.

6. The method for preparing a deuterated drug impurity O-desmethylvenlafaxine-d10 according to claim 1, characterized in that: In S4, nuclear magnetic resonance (NMR) spectroscopy is used to confirm the deuteration status of the target compound, and deuterated solvents are used for NMR testing.

7. The method for preparing a deuterated drug impurity O-desmethylvenlafaxine-d10 according to claim 1, characterized in that: The reaction conditions included in S1 and S2 include: temperature 20-30°C, pressure 1-3atm, and reaction time 4-6 hours.

8. The method for preparing a deuterated drug impurity O-desmethylvenlafaxine-d10 according to claim 1, characterized in that: in, The preparation of venlafaxine comprises a. Add 300 mL of solvent, 20 g of NaOH, and 12.5-30 g of catalyst to a reaction vessel, stir for 15-30 min, cool to 10-20 ° C, add 150 g of 2-(4-methoxyphenyl)ethylamine and 100-200 g of cyclohexanone, stir for 3-4 h at 10-20 ° C, add 900-1000 mL of deionized water, stir for 30-40 min, filter, and dry at 55 ° C to obtain an intermediate; b. Add 160-250 g of the intermediate, 1000 mL of deionized water, 200-300 mL of formic acid, and 150-200 mL of methanol to a reaction vessel, heat to reflux, stir for 20-30 h, recover the solvent under reduced pressure until dry, add 400-600 mL of deionized water and 400-600 mL of ethyl acetate, adjust the pH to 10 with a 10% NaOH aqueous solution, allow to stand for stratification, collect the upper organic phase, dry over anhydrous sodium sulfate, filter, add 120-180 mL of salt solution to the filtrate at 5-15 ° C, stir and crystallize for 2-3.5 h, filter, and wash the filter cake with ethyl acetate to obtain venlafaxine.

9. The method for preparing a deuterated drug impurity O-desmethylvenlafaxine-d10 according to claim 8, characterized in that: The solvent in step a is prepared by mixing deionized water and methanol in a volume ratio of 1:1; the catalyst is any one of PEG, cyclodextrin, benzyltriethylammonium chloride, tetrabutylammonium bromide, and tetrabutylammonium chloride.

10. The method for preparing a deuterated drug impurity O-desmethylvenlafaxine-d10 according to claim 8, characterized in that: The mass ratio of the upper organic phase to anhydrous sodium sulfate is 100:1-2; the salt-forming solution in step b is 30% isopropanol hydrochloride by mass.